Evidence map›Paper›PMID 38917443›Full record

ArticleJournal of neuropathology and experimental neurology2024

In situ seeding assay: A novel technique for direct tissue localization of bioactive tau.

Romain Perbet, Anastasie Mate de Gerando, Calina Glynn, Cameron Donahue, Angelica Gaona, Raquel N Taddei, Teresa Gomez-Isla, Aurelien Lathuiliere, Bradley T Hyman

Abstract read
In one paragraph

Article in Journal of neuropathology and experimental neurology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Romain PerbetNeurology Department, Massachusetts General Hospital, Harvard University, Boston, MA, United States.ORCID 0000-0001-5974-4061
Anastasie Mate de GerandoNeurology Department, Massachusetts General Hospital, Harvard University, Boston, MA, United States.
Calina GlynnNeurology Department, Massachusetts General Hospital, Harvard University, Boston, MA, United States.
Cameron DonahueNeurology Department, Massachusetts General Hospital, Harvard University, Boston, MA, United States.
Angelica GaonaNeurology Department, Massachusetts General Hospital, Harvard University, Boston, MA, United States.
Raquel N TaddeiNeurology Department, Massachusetts General Hospital, Harvard University, Boston, MA, United States.
Teresa Gomez-IslaNeurology Department, Massachusetts General Hospital, Harvard University, Boston, MA, United States.
Aurelien LathuiliereNeurology Department, Massachusetts General Hospital, Harvard University, Boston, MA, United States.
Bradley T HymanNeurology Department, Massachusetts General Hospital, Harvard University, Boston, MA, United States.

Funding

Research Education ComponentP30AG062421 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI STEVEN E ARNOLD · 2019 to 2026
$36.5M
Are multiple tau species toxic in Alzheimer's Disease?RF1AG059789 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI HYMAN, BRADLEY T. · 2018 to 2018
$2.7M
Synergy between amyloid and tau in Alzheimer's DiseaseRF1AG058674 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI HYMAN, BRADLEY T. · 2018 to 2018
$2.6M
Complexity and Heterogeneity of Alzheimer diseaseR56AG061196 · NIA · MASSACHUSETTS GENERAL HOSPITAL · PI HYMAN, BRADLEY T. · 2019 to 2019
$654k
foundation Philippe ChatrierNIA NIH HHS P30 AG062421NIA NIH HHS R56 AG061196NIA NIH HHS RF1 AG058674NIA NIH HHS RF1 AG059789NIH HHS R56AG061196Philip foundationPhilip foundation and the foundation Philippe ChatrierRainwater Foundation Tau ConsortiumRainwater Foundation Tau Consortium (BTH) NIH R56AG061196
6 · The paper itself

Abstract

Proteins exhibiting prion-like properties are implicated in tauopathies. The prion-like traits of tau influence disease progression and correlate with severity. Techniques to measure tau bioactivity such as RT-QuIC and biosensor cells lack spatial specificity. Therefore, we developed a histological probe aimed at detecting and localizing bioactive tau in situ. We first induced the recruitment of a tagged probe by bioactive Tau in human brain tissue slices using biosensor cell lysates containing a fluorescent probe. We then enhanced sensitivity and flexibility by designing a recombinant probe with a myc tag. The probe design aimed to replicate the recruitment process seen in prion-like mechanisms based on the cryo-EM structure of tau aggregates in Alzheimer disease (AD). Using this novel probe, we observed selective staining of misfolded tau in pre- and post-synaptic structures within neurofibrillary tangles and neurites, whether or not associated with neuritic plaques. The probe specifically targeted AD-associated bioactive tau and did not recognize bioactive tau from other neurodegenerative diseases. Electron microscopy and immunolabeling further confirmed the identification of fibrillar and non-fibrillar tau. Finally, we established a correlation between quantifying bioactive tau using this technique and gold standard biosensor cells. This technique presents a robust approach for detecting bioactive tau in AD tissues and has potential applications for deciphering mechanisms of tau propagation and degradation pathways.

Indexed as

Alzheimer DiseaseBraintau ProteinsBiosensing TechniquesHumansNeurofibrillary TanglesTauopathiestau ProteinsAlzheimer diseaseastrocytehistopathologyprion-likesynapsetautauopathies

Identifiers

PMID38917443
PMCPMC11413465

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.